CA Patent

CA2468649C — Adenosine a2a receptor antagonists

Assigned to Merck Sharp and Dohme LLC · Expires 2009-03-10 · 17y expired

What this patent protects

Disclosed herein are compounds having the structural formula (A) including pharmaceutically acceptable salts or solvates of said compound, wherein X, Y , Q and R are as defined in the specification; pharmaceutical compositions thereof; methods of treating central nervous system d…

USPTO Abstract

Disclosed herein are compounds having the structural formula (A) including pharmaceutically acceptable salts or solvates of said compound, wherein X, Y , Q and R are as defined in the specification; pharmaceutical compositions thereof; methods of treating central nervous system diseases by administerin g the compound of the present invention to a patient in need of such treatment , and processes for preparing the compound of this invention.

Drugs covered by this patent

Patent Metadata

Patent number
CA2468649C
Jurisdiction
CA
Classification
—
Expires
2009-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.